In this study, levosimendan compared with placebo did show improvement in symptoms at 5 days, reduction in NT-ProBNP levels, and shorter hospitalization duration, but these benefits were accompanied by an increase in adverse events such as hypotension, ventricular tachycardia, and atrial fibrillation. Here, NPPB is linked to hypotensive disorder.